-
VillageMD acquires Summit WBA for $9 billion to strengthen its healthcare strategy
Time of Update: 2022-12-04
CareCentrix's business includes not only home care, but also management services for insurance companies and hospitals to reduce readmissions rates, from discharge to home rehabilitation.
CareCentrix's business includes not only home care, but also management services for insurance companies and hospitals to reduce readmissions rates, from discharge to home rehabilitation.
-
What should be done to build a benign ecology of innovative drugs into the deep water area?
Time of Update: 2022-12-04
Borrow Lilac Garden Insight On the occasion of the ninth anniversary of the database, Lilac Garden specially invited Professor Shao Rong, Executive Dean of the Institute of Drug Regulatory Science, Ch
-
Over $500 million! Moderna partnered with Harbour Pharmaceutical, and its shares soared 17%
Time of Update: 2022-12-04
HK) Nona BioModerna (ModernaTX, NASDAQ: MRNA) fully human heavy-chain antibody platform HCAb gene immunotherapy Under the agreement, Moderna will receive a set of exclusive, sublicensable licenses for multiple target sequences developed by the HCAb platform for gene therapy research and development, with overall responsibility for all aspects related to its development, manufacturing, regulation and commercialization.
-
Arrowhead Pharmaceuticals sells a concession interest in olpasiran for $400 million
Time of Update: 2022-12-04
Olpasiran, a product we developed and licensed to Amgen for further clinical development and commercialization, has the potential to benefit millions of patients worldwide by reducing the risk of cardiovascular disease.
-
FDA Generic Approval Data Trends and Analysis for FY 2022
Time of Update: 2022-11-26
The number of requests for information (IRs) in FY2022 was 4,370, compared to 4,313 in FY2021, and the number of disciplinary review letters was 2,484, an increase from FY2021 9%。 The FDA began reporting IR and DRL statistics based on GDUFA II starting in fiscal year 2018.
-
Continuous Increase: Layout and strategy of multichannel marketing leaders
Time of Update: 2022-11-26
In addition, the report also collects some effective suggestions from industry experts and doctors on the future improvement of multi-channel digital marketing From the perspective of treatment areas, the digital channel investment of chronic disease products is generally more active, and the more active treatment areas covered by digital activities are hypoglycemic field and antibacterial products; Affected by centralized procurement, foreign companies have optimized multi-channel coverage for different product categories and implemented strategies tailored to local conditions.
-
Strength rating of Chinese pharmaceutical universities!
Time of Update: 2022-11-26
01 Rating of pharmaceutical strength of Chinese universities01 Rating of pharmaceutical strength of Chinese universitiesThe 2022 Medical Strength Selection (see the end of the article for the results)
-
A collection of novel drug targets
Time of Update: 2022-11-26
This article summarizes the emerging targets of recent drug development, covering glioblastoma, pancreatic cancer, gastric cancer peritoneal metastases, small cell lung cancer, lupus nephritis, obesit
-
In the sleeping tens of billions of market, how will the marketization of medical data elements leverage medical data?
Time of Update: 2022-11-26
"Such a large-scale digital project with practical value can achieve a win-win situation, which can not only achieve its own goals of supporting industry applications, such as benefiting the people, providing medical service governance, and improving management efficiency, but also a key practice for high-quality data aggregation in the province.
-
After ADC, can PDC become a new direction for targeted therapy?
Time of Update: 2022-11-26
As an anti-cancer drug delivery modality, PDCs have the advantage of covalently modifying a ligand peptide that can target specific cell surface receptors or biomarkers at the tumor site for long-lasting efficacy, thereby imparting an overall desirable pharmacokinetic profile.
-
As multinational pharmaceutical companies accelerated the entry of innovative products into the Chinese market, Merck Sharp & Dohme approved another new drug for clinical trials
Time of Update: 2022-11-26
In addition to MK-0616 capsules, on May 13 this year, according to the NMPA website, Merck's new antiviral drug letermovir injection dosage form has also been approved for marketing.
-
26.5 billion, new medical infrastructure released water
Time of Update: 2022-11-26
According to the Notice on Issuing the 2022 Central Infrastructure Investment Budget in the Health Sector (Third Batch), it is necessary to expand the achievements of public health prevention and control and treatment, strengthen the construction of centralized isolation and treatment facilities to respond to large-scale epidemics, accelerate the expansion of high-quality medical resources and balanced regional layout, comprehensively protect the health of key groups, and promote the inheritance and innovative development of traditional Chinese medicine.
-
Pharmaceutical companies are adopting a contraction strategy, and frequent asset sales are the norm
Time of Update: 2022-11-26
Judging from public information, Harbour Pharmaceutical's business adjustment actions have been very frequent in the past two months, not only selling factories, but also two core products under research have been terminated and sold respectively.
-
Is insulin free? The $8 oolong case on Twitter "knocked out" Lilly's 20 billion market value, and also poked out the proposition of the century in the pharmaceutical industry...
Time of Update: 2022-11-26
" ”Not only Roche, in the past decade, AD is like a huge black hole, swallowing the investment of major pharmaceutical companies, people regret research and development not only in the fact that most of these products have gone to phase III clinical failure, and the "result" is always a foot away.
-
【CDE Acceptance Overview】CDE Acceptance Status from November 7th to November 13th
Time of Update: 2022-11-26
There are 7 Class 5 drug acceptance numbers, namely:There are 7 Class 5 drug acceptance numbers, namely: The acceptance status of the consistency evaluation is as follows:The acceptance status of the consistency evaluation is as follows: From November 7 to November 13, CDE accepted a total of 124 drug applications (excluding supplementary applications and import re-registration, the same below).
-
With the separation of the Medical Administration and Hospital Authority, the Medical Administration Department has real power, and epidemic prevention is still the first priority
Time of Update: 2022-11-26
In order to cope with the shift in the focus of epidemic prevention in the future, it is necessary to build three lines of defense - the National Disease Control Administration, which is responsible for monitoring and early warning, the Department of Medical Emergencies, which leads public health, and the Department of Medical Administration, which is in charge of medical institutions.
-
Centralized procurement of unselected varieties, Jiangsu began to adjust the price and payment standards in steps
Time of Update: 2022-11-26
Those who failed to pass the consistency evaluation of quality and efficacyFor unselected products that have not adjusted the price (upper limit of negotiation) as required, their procurement and use will be included in the scope of key monitoring, and the procurement situation of medical institutions will be regularly reported.
-
Lowering the diagnostic criteria for hypertension? More than 200 million incremental patients, hundreds of billions of tracks to make waves
Time of Update: 2022-11-26
Life intervention content of non-high-risk patients, source "New Guidelines"In addition, just as digital therapeutics for diabetes have led to the development of CGM, chronic disease management for hypertension is likely to drive the ambulatory blood pressure monitoring market in the future.
-
PD-1 R&D experience, ADC is not applicable to the first field
Time of Update: 2022-11-26
There is great uncertainty in the characteristics, and these factors are intertwined and affect the whole bodyIn view of this, the interviewed companies all mentioned that the R&D process should fully understand the advantages and disadvantages of their own product design, such as bystander effect, target affinity, toxin characteristics, etc.
-
Diabetes "medicine king" sold 1 billion! Yangtze River, China and the United States East China broke the screen of foreign investment, and 14 exclusive proprietary Chinese medicines were sold hot
Time of Update: 2022-11-26
"Yaowang" sold more than 1 billion, Yangtze River, Sino-US East China advanced into the TOP20 brand; 14 exclusive products support 78% of the market for diabetic proprietary Chinese medicine, Baiyunshan ranks in the TOP1, with an amazing rise in Ling, and the new Chinese medicine drugs approved for marketing in 2020 are on the TOP20 list.
